ESLA (STOCKS)
Estrella Immunopharma, Inc. Common Stock
$1.700800
-0.139200 (-7.57%)
Prev close: $1.840000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Cheng Liu
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $75.94M
- Employees
- —
- P/E (TTM)
- -4.90
- P/B (TTM)
- -6.41
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
4
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q2)
|
$-0.35 | $-0.18 | -0.1664 | -90.63% |
|
Sep 2025 (Q1)
|
$-0.13 | $-0.19 | +0.0638 | +32.92% |
|
Jun 2025 (Q4)
|
$-0.15 | $-0.11 | -0.0378 | -33.69% |
|
Mar 2025 (Q3)
|
$-0.06 | $-0.11 | +0.0522 | +46.52% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $13.06M |
| Research and Development | $10.25M |
| Other Operating Expenses | $2.81M |
| Operating Income/Loss | -$13.06M |
| Income/Loss From Continuing Operations After Tax | -$13.06M |
| Income/Loss From Continuing Operations Before Tax | -$13.06M |
| Income Tax Expense/Benefit | $838.00 |
| Net Income/Loss | -$13.06M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$13.06M |
| Net Income/Loss Available To Common Stockholders, Basic | -$13.06M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.35 |
| Diluted Earnings Per Share | -$0.35 |
| Basic Average Shares | 36,820,810 |
| Diluted Average Shares | 36,820,810 |
| Assets | $3.18M |
| Current Assets | $1.68M |
| Noncurrent Assets | $1.50M |
| Liabilities | $13.54M |
| Current Liabilities | $13.54M |
| Noncurrent Liabilities | $0.00 |
| Equity | -$10.37M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$10.37M |
| Liabilities And Equity | $3.18M |
| Net Cash Flow From Operating Activities | -$1.79M |
| Net Cash Flow From Operating Activities, Continuing | -$1.79M |
| Net Cash Flow From Investing Activities | -$467.39K |
| Net Cash Flow From Investing Activities, Continuing | -$467.39K |
| Net Cash Flow From Financing Activities | $2.25M |
| Net Cash Flow From Financing Activities, Continuing | $2.25M |
| Net Cash Flow | $0.00 |
| Net Cash Flow, Continuing | $0.00 |
| Comprehensive Income/Loss | -$13.06M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$13.06M |
| Other Comprehensive Income/Loss | $0.00 |